Ipsen Pharma S.a.s.

Societe De Conseils De Recherches Et D'applications Scientifiques Sas

Ipsen Pharma

Yeelana Shen

Zheng Xin Dong

Sun H Kim

Michael DeWitt Culler

Christophe Thurieau

Daniel B Deoliveira

Jeanne Mary Comstock

John Stuart Eynon

Jundong Zhang

Michael Dewitt Culler

Sun Hyuk Kim

Christophe Alain Thurieau

The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.

Somatostatin-dopamine chimeric analogs

The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.

Ghrelin analogs

There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.

Analogues of glucose-dependent insulinotropic polypeptide

The invention comprises peptidyl analogs according to formulae (I) or (II) as depicted below: wherein the definitions of Ato Aand Rto Rare provided for in the specification for each of formulae (I) and (II), pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of a compound of formula (I), that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.

Analogs of ghrelin

The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.

Peptide-cytotoxic conjugates

A family of peptides and peptidomimetic compounds useful as GHS analogs according to either formula (I) or (II) as depicted below: or a pharmaceutically acceptable salts thereof, wherein the variables are as defined in the specification. 

Growth hormone secretagogues

The present invention is directed to imidazolyl derivatives of formula (II), wherein the variables are defined in the specification, which are useful as prenyl transeferase inhibitors.

Growing community of inventors

Franklin, MA, United States of America

Yeelana Shen